Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Biotech in the time of corona
Adam's Take

Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

By Adam Feuerstein

Biotech in the time of corona
Adam's Take

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

By Adam Feuerstein

Biotech in the time of corona
Adam's Take

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

By Adam Feuerstein

Biotech in the time of corona
Adam's Take

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

By Adam Feuerstein

Biotech in the time of corona
Adam's Take

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

By Adam Feuerstein

transmission electron micrograph covid19
Adam's Take

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

By Adam Feuerstein

Adam's Take

TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

By Adam Feuerstein

Adam's Take

Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug

By Adam Feuerstein

Amarin Transcript
Adam's Take

‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug

By Adam Feuerstein

Daniel O'Day STAT Summit
Adam's Take

Investor impatience with Gilead reclamation project sparks acquisition chatter

By Adam Feuerstein

Biotech Mt Rushmore
Adam's Take

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

By Adam Feuerstein

Adam's Take

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

By Adam Feuerstein

JPM 2020 Lombard St
Adam's Take

The truth about JPM: Less is more

By Adam Feuerstein

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

Adam's Take

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

By Adam Feuerstein

Adam's Take

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

By Adam Feuerstein

2010- 2019 Medicine
Biotech

STAT’s guide to the most important, beneficial drugs approved in the past decade

By Adam Feuerstein and Matthew Herper

Good/Bad CEO 2017
Adam's Take

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

By Adam Feuerstein

BAD CEOS
Adam's Take

And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!

By Adam Feuerstein

Good CEOs
Adam's Take

Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!

By Adam Feuerstein

Adam's Take

The good, the bad, and the really, really ugly behind Sarepta’s drug approval

By Adam Feuerstein

Adam's Take

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

By Adam Feuerstein

Adam's Take

Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval

By Adam Feuerstein

Adam's Take

A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling

By Adam Feuerstein

Adam's Take

The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results

By Adam Feuerstein

Vivek Ramaswamy
Adam's Take

Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

By Adam Feuerstein

Adam's Take

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

By Adam Feuerstein

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Adam's Take

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy